文献速递MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

老年晚期MDS:5-阿扎胞苷后异基因移植与持续5-阿扎胞苷治疗的供者可用性比较(VidazaAllo研究)

Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study).
PubMed 文献 · J Clin Oncol · 2021-07-20

PURPOSE: In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-related mortality (TRM) limits its broader use in elderly patients with MDS.…

要点

  • 5-阿扎胞苷诱导后仅67%患者可进入后续分配,7%在分配前死亡。
  • 移植后1年治疗相关死亡率累积发生率为19%。
  • 移植组3年无事件生存率34%,持续5-阿扎胞苷组0%,差异显著。

核心结论

  • 在55-70岁高危MDS患者中,减低强度预处理异基因移植较持续5-阿扎胞苷治疗显著改善无事件生存。
  • 5-阿扎胞苷桥接移植前因疾病进展、死亡和不良事件导致相当比例的脱落。

研究设计与样本

  • 患者先接受4-6周期5-阿扎胞苷,随后根据供者可用性分配至HLA相合减低强度预处理异基因移植或继续5-阿扎胞苷。

主要发现

  • 162例启动5-阿扎胞苷诱导,仅108例(67%)符合后续分配条件(移植81例,继续5-阿扎胞苷27例)。
  • 未分配原因包括疾病进展26例、死亡12例、其他原因16例;7%在分配前死亡。
  • 移植后1年治疗相关死亡率累积发生率为19%。

临床怎么用

  • 对55-70岁高危MDS患者,若有HLA相合供者,可考虑5-阿扎胞苷桥接后行减低强度预处理异基因移植以改善无事件生存。
  • 桥接期间需密切监测疾病进展和不良事件,因脱落率较高。

局限性

  • 仅67%的诱导患者进入分配阶段,样本量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In contrast to 5-azacytidine (5-aza), allogeneic stem-cell transplantation (HSCT) represents a curative treatment strategy for patients with myelodysplastic syndromes (MDS), but therapy-related mortality (TRM) limits its broader use in elderly patients with MDS. The present prospective multicenter study compared HSCT following 5-aza pretreatment with continuous 5-aza treatment in patients with higher-risk MDS age 55-70 years. METHODS: One hundred ninety patients with a median age of 63 years were enrolled. Patients received 4-6 cycles of 5-aza followed by HLA-compatible HSCT after reduced-intensity conditioning or by continuous 5-aza if no donor was identified. RESULTS: Twenty-eight patients did not fulfill inclusion criteria (n = 20), died (n = 2) withdrew informed consent (n = 5), or were excluded for an unknown reason (n = 1). 5-aza induction started in 162 patients, but only 108 (67%) were eligible for subsequent allocation to HSCT (n = 81) or continuation of 5-aza (n = 27) because of disease progression (n = 26), death (n = 12), or other reasons (n = 16). Seven percent died during 5-aza before treatment allocation. The cumulative incidence of TRM after HSCT at 1 year was 19%. The event-free survival and overall survival after 5-aza pretreatment and treatment allocation at 3 years were 34% (95% CI, 22 to 47) and 50% (95% CI, 39 to 61) after allograft and 0% and 32% (95% CI, 14 to 52) after continuous 5-aza treatment (P < .0001 and P = .12), respectively. Fourteen patients progressing after continuous 5-aza received a salvage allograft from an alternative donor, and 43% were alive at last follow-up. CONCLUSION: In older patients with MDS, reduced-intensity conditioning HSCT resulted in a significantly improved event-free survival in comparison with continuous 5-aza therapy. Bridging with 5-aza to HSCT before is associated with a considerable rate of dropouts because of progression, mortality, and adverse events.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kröger N, Sockel K, Wolschke C, et al. Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol. 2021. PMID: 34283629. doi:10.1200/JCO.20.02724

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。